FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308294088> ?p ?o ?g. }

• W4308294088 endingPage "211" @default.
• W4308294088 startingPage "201" @default.
• W4308294088 abstract "Acetazolamide inhibits proximal tubular sodium reabsorption and improved decongestion in the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. It remains unclear whether the decongestive effects of acetazolamide differ across the spectrum of left ventricular ejection fraction (LVEF).This is a prespecified analysis of the randomized, double-blind, placebo-controlled ADVOR trial that enrolled 519 patients with acute heart failure (HF), clinical signs of volume overload (eg, edema, pleural effusion, or ascites), NTproBNP (N-terminal pro-B-type natriuretic peptide) >1000 ng/L, or BNP (B-type natriuretic peptide) >250 ng/mL to receive intravenous acetazolamide (500 mg once daily) or placebo in addition to standardized intravenous loop diuretics (twice that of the oral home maintenance dose). Randomization was stratified according to LVEF (≤40% or >40%). The primary end point was successful decongestion, defined as the absence of signs of volume overload within 3 days from randomization without the need for mandatory escalation of decongestive therapy because of poor urine output.Median LVEF was 45% (25th to 75th percentile; 30% to 55%), and 43% had an LVEF ≤40%. Patients with lower LVEF were younger and more likely to be male with a higher prevalence of ischemic heart disease, higher NTproBNP, less atrial fibrillation, and lower estimated glomerular filtration rate. No interaction on the overall beneficial treatment effect of acetazolamide to the primary end point of successful decongestion (OR, 1.77 [95% CI, 1.18-2.63]; P=0.005; all P values for interaction >0.401) was found when LVEF was assessed per randomization stratum (≤40% or >40%), or as HF with reduced ejection fraction, HF with mildly reduced ejection fraction, and HF with preserved ejection fraction, or on a continuous scale. Acetazolamide resulted in improved diuretic response measured by higher cumulative diuresis and natriuresis and shortened length of stay without treatment effect modification by baseline LVEF (all P values for interaction >0.160).When added to treatment with loop diuretics in patients with acute decompensated HF, acetazolamide improves the incidence of successful decongestion and diuretic response, and shortens length of stay without treatment effect modification by baseline LVEF.URL: https://www.gov; Unique identifier: NCT03505788." @default.
• W4308294088 created "2022-11-10" @default.
• W4308294088 creator A5005788624 @default.
• W4308294088 creator A5013727186 @default.
• W4308294088 creator A5023320363 @default.
• W4308294088 creator A5024444052 @default.
• W4308294088 creator A5032967663 @default.
• W4308294088 creator A5035023430 @default.
• W4308294088 creator A5046318945 @default.
• W4308294088 creator A5050226243 @default.
• W4308294088 creator A5051270747 @default.
• W4308294088 creator A5055597403 @default.
• W4308294088 creator A5079600079 @default.
• W4308294088 creator A5082623751 @default.
• W4308294088 creator A5086624399 @default.
• W4308294088 creator A5088059687 @default.
• W4308294088 date "2023-01-17" @default.
• W4308294088 modified "2023-10-01" @default.
• W4308294088 title "Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial" @default.
• W4308294088 cites W2080740174 @default.
• W4308294088 cites W2117890587 @default.
• W4308294088 cites W2139359396 @default.
• W4308294088 cites W2187526770 @default.
• W4308294088 cites W2736262452 @default.
• W4308294088 cites W2784257687 @default.
• W4308294088 cites W2890636056 @default.
• W4308294088 cites W2907983377 @default.
• W4308294088 cites W2944409590 @default.
• W4308294088 cites W3000607175 @default.
• W4308294088 cites W3160504440 @default.
• W4308294088 cites W3193598686 @default.
• W4308294088 cites W3199575284 @default.
• W4308294088 cites W339545475 @default.
• W4308294088 cites W4214868559 @default.
• W4308294088 cites W4225396975 @default.
• W4308294088 cites W4283320810 @default.
• W4308294088 cites W4293872386 @default.
• W4308294088 doi "https://doi.org/10.1161/circulationaha.122.062486" @default.
• W4308294088 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36335479" @default.
• W4308294088 hasPublicationYear "2023" @default.
• W4308294088 type Work @default.
• W4308294088 citedByCount "5" @default.
• W4308294088 countsByYear W43082940882023 @default.
• W4308294088 crossrefType "journal-article" @default.
• W4308294088 hasAuthorship W4308294088A5005788624 @default.
• W4308294088 hasAuthorship W4308294088A5013727186 @default.
• W4308294088 hasAuthorship W4308294088A5023320363 @default.
• W4308294088 hasAuthorship W4308294088A5024444052 @default.
• W4308294088 hasAuthorship W4308294088A5032967663 @default.
• W4308294088 hasAuthorship W4308294088A5035023430 @default.
• W4308294088 hasAuthorship W4308294088A5046318945 @default.
• W4308294088 hasAuthorship W4308294088A5050226243 @default.
• W4308294088 hasAuthorship W4308294088A5051270747 @default.
• W4308294088 hasAuthorship W4308294088A5055597403 @default.
• W4308294088 hasAuthorship W4308294088A5079600079 @default.
• W4308294088 hasAuthorship W4308294088A5082623751 @default.
• W4308294088 hasAuthorship W4308294088A5086624399 @default.
• W4308294088 hasAuthorship W4308294088A5088059687 @default.
• W4308294088 hasBestOaLocation W43082940881 @default.
• W4308294088 hasConcept C126322002 @default.
• W4308294088 hasConcept C142724271 @default.
• W4308294088 hasConcept C164705383 @default.
• W4308294088 hasConcept C168563851 @default.
• W4308294088 hasConcept C203092338 @default.
• W4308294088 hasConcept C204243189 @default.
• W4308294088 hasConcept C204787440 @default.
• W4308294088 hasConcept C27081682 @default.
• W4308294088 hasConcept C2777405951 @default.
• W4308294088 hasConcept C2778198053 @default.
• W4308294088 hasConcept C2779295919 @default.
• W4308294088 hasConcept C71924100 @default.
• W4308294088 hasConcept C78085059 @default.
• W4308294088 hasConceptScore W4308294088C126322002 @default.
• W4308294088 hasConceptScore W4308294088C142724271 @default.
• W4308294088 hasConceptScore W4308294088C164705383 @default.
• W4308294088 hasConceptScore W4308294088C168563851 @default.
• W4308294088 hasConceptScore W4308294088C203092338 @default.
• W4308294088 hasConceptScore W4308294088C204243189 @default.
• W4308294088 hasConceptScore W4308294088C204787440 @default.
• W4308294088 hasConceptScore W4308294088C27081682 @default.
• W4308294088 hasConceptScore W4308294088C2777405951 @default.
• W4308294088 hasConceptScore W4308294088C2778198053 @default.
• W4308294088 hasConceptScore W4308294088C2779295919 @default.
• W4308294088 hasConceptScore W4308294088C71924100 @default.
• W4308294088 hasConceptScore W4308294088C78085059 @default.
• W4308294088 hasFunder F4320306621 @default.
• W4308294088 hasIssue "3" @default.
• W4308294088 hasLocation W43082940881 @default.
• W4308294088 hasLocation W43082940882 @default.
• W4308294088 hasLocation W43082940883 @default.
• W4308294088 hasLocation W43082940884 @default.
• W4308294088 hasOpenAccess W4308294088 @default.
• W4308294088 hasPrimaryLocation W43082940881 @default.
• W4308294088 hasRelatedWork W2051712573 @default.
• W4308294088 hasRelatedWork W2077083067 @default.
• W4308294088 hasRelatedWork W2091139515 @default.
• W4308294088 hasRelatedWork W2355594703 @default.
• W4308294088 hasRelatedWork W2361407492 @default.

• next